JavaScript seems to be disabled in your browser. You must have JavaScript enabled in your browser to utilize the functionality of this website.
There are no items in your shopping cart
Featured Products
Axon 3901
CAS [2097002-61-2]
MF C20H21FN6OMW 380.42
LOXO-195 is an oral, second generation TRK inhibitor being made to address the acquired resistance to first generation TRK inhibitor (such as LOXO-101 (Axon 3407)). LOXO-195 potently and selectively inhibits, with minimal activity against other kinases, pan-TRKs (with potency on par with that of LOXO-101), and more importantly, abrogates resistance in TRK fusion–positive cancers that acquired kinase domain mutations due to the treatment of existing TRK inhibitors. Displays high oral bioavailability and favorable PK in animals.
KEYWORDS: LOXO-195 | Supplier | Trk inhibitor | Selitrectinib | LOXO195 | LOXO 195 | CT-LX195 | CAS [2097002-61-2] | Neurotrophin | Trk | inhibitor | Receptors
(3aR,10R)-5-Fluoro-1,2,3,3a,8,9,10,11-octahydro-10-methyl-12H-15,17-Ethenopyrazolo[3,4-d]pyrido[2,3-k]pyrrolo[2,1-m][1,3,7]triazacyclotridecin-12-one,
[2097002-61-2]
The purity of Axon Ligands™ is confirmed by HPLC-MS, 1H-NMR and/or microanalysis. Analytical data are available upon request.
Caution: Axon Ligands™ are not fully tested. They are for research purposes only! Not for human consumption!
* Required Fields